Paul A. Grayson Sells 86,244 Shares of Skye Bioscience, Inc. Stock

SKYE Stock  USD 2.46  0.20  7.52%   
About 67% of Skye Bioscience,'s investor base is looking to short. The analysis of the overall investor sentiment regarding Skye Bioscience, Common suggests that many traders are alarmed. The current market sentiment, together with Skye Bioscience,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Skye Bioscience, Common stock news signals to limit their universe of possible portfolio assets.
  
Skye Bioscience, Inc. Director Paul A. Grayson sold 86,244 shares of the firms stock in a transaction on Monday, November 18th. The stock was sold at an average price of 4.99, for a total value of 430,357.56. Following the transaction, the director now owns 259,701 shares in the company, valued

Read at thelincolnianonline.com
news
  

Skye Bioscience, Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Skye Bioscience, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Skye Bioscience, Fundamental Analysis

We analyze Skye Bioscience,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Skye Bioscience, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Skye Bioscience, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Beta

Beta Comparative Analysis

Skye Bioscience, is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Skye Bioscience, Common Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Skye Bioscience, stock to make a market-neutral strategy. Peer analysis of Skye Bioscience, could also be used in its relative valuation, which is a method of valuing Skye Bioscience, by comparing valuation metrics with similar companies.

Peers

Skye Bioscience, Related Equities

VXRTVaxart   19.67   
0%
100.0%
PASGPassage Bio   1.54   
0%
7.0%
LRMRLarimar Therapeutics   1.00   
5.0%
0%
SILOSilo Pharma   1.05   
5.0%
0%
STOKStoke Therapeutics   1.60   
8.0%
0%
ALECAlector   2.20   
11.0%
0%
GLUEMonte Rosa   2.22   
11.0%
0%
RVMDRevolution Medicines   2.38   
12.0%
0%
JAGXJaguar Animal   2.83   
14.0%
0%
BDTXBlack Diamond   4.78   
24.0%
0%
CABACabaletta Bio   8.03   
40.0%
0%
TNXPTonix Pharmaceuticals   8.11   
41.0%
0%

Complementary Tools for Skye Stock analysis

When running Skye Bioscience,'s price analysis, check to measure Skye Bioscience,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Skye Bioscience, is operating at the current time. Most of Skye Bioscience,'s value examination focuses on studying past and present price action to predict the probability of Skye Bioscience,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Skye Bioscience,'s price. Additionally, you may evaluate how the addition of Skye Bioscience, to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Stocks Directory
Find actively traded stocks across global markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope